Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Deerfield Management Company, L.P. (Series C)

SEC CIK
0001009258
Latest filing
Aug 14, 2026

The latest 13F from Deerfield Management Company, L.P. (Series C) covers Q2 2026 (filed Aug 14, 2026): 82 long positions worth $9.59B. The top 10 holdings make up 53.2% of the portfolio, and the largest is Nuvalent, Inc. (NUVL) at 22.2%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Full comparison

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

New
13
Est. +$684.7M
Added
13
Est. +$292.8M
Reduced
11
Est. −$451.4M
Sold out
13
Est. −$618.5M

Top 5 holdings

Share of this quarter's portfolio value

  1. NUVLNuvalent, Inc.
    22.2%$2.13BHistory
  2. Brookdale Sr Living Inc112463AF1
    6.1%$585.7M
  3. RVMDRevolution Medicines, Inc.
    4.7%$448.0MHistory
  4. PRAXPraxis Precision Medicines, Inc.
    3.4%$322.5MHistory
  5. VTRSViatris Inc
    3.3%$320.9MHistory

Share of portfolio

Top 5 holdings and the other 77 positions, by share of portfolio value

  1. NUVL22.2%
  2. Brookdale Sr Living Inc6.1%
  3. RVMD4.7%
  4. PRAX3.4%
  5. VTRS3.3%
  6. Other 77 positions60.3%

Biggest buys

New and added positions, by estimated amount bought

  1. Revolution Medicines, Inc.76155XAA8
    +$251.7MNew
  2. GMABGenmab A/S
    +$121.0MAddedHistory
  3. Celcuity Inc.15102KAB6
    +$113.8MNew
  4. MLYSMineralys Therapeutics, Inc.
    +$106.8MNewHistory
  5. BSXBoston Scientific Corp
    +$56.1MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. Revolution Medicines, Inc.76155XAA8
    +2.63 pp0.0% → 2.6%
  2. RVMDRevolution Medicines, Inc.
    +2.04 pp2.6% → 4.7%History
  3. GMABGenmab A/S
    +1.19 pp0.8% → 2.0%History
  4. Celcuity Inc.15102KAB6
    +1.19 pp0.0% → 1.2%
  5. MLYSMineralys Therapeutics, Inc.
    +1.11 pp0.0% → 1.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. Mirum Pharmaceuticals, Inc.604749AB7
    −$209.4MSold out
  2. COGTCogent Biosciences, Inc.
    −$156.3MReducedHistory
  3. CPRXCatalyst Pharmaceuticals, Inc.
    −$97.6MSold outHistory
  4. NBIXNeurocrine Biosciences Inc
    −$80.4MSold outHistory
  5. DAWNDay One Biopharmaceuticals, Inc.
    −$79.8MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. Mirum Pharmaceuticals, Inc.604749AB7
    −2.47 pp2.5% → 0.0%
  2. COGTCogent Biosciences, Inc.
    −2.09 pp4.1% → 2.0%History
  3. CPRXCatalyst Pharmaceuticals, Inc.
    −1.15 pp1.2% → 0.0%History
  4. INSPInspire Medical Systems, Inc.
    −1.04 pp1.6% → 0.6%History
  5. NBIXNeurocrine Biosciences Inc
    −0.95 pp0.9% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$9.59B
+$1.11B (+13.1%) vs. prior quarter
Positions
82
0 vs. prior quarter
Top 10 concentration
53.2%
Top 10 as share of value
Turnover
10.8%
Q2 2026, one quarter
Average holding period
11.3 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $9.59B (Q2 2026)

Q1 2021: $4.76BQ2 2021: $5.63BQ3 2021: $5.11BQ4 2021: $4.75BQ1 2022: $4.47BQ2 2022: $4.75BQ3 2022: $5.01BQ4 2022: $4.83BQ1 2023: $4.49BQ2 2023: $4.68BQ3 2023: $4.54BQ4 2023: $5.42BQ1 2024: $5.75BQ2 2024: $6.01BQ3 2024: $6.69BQ4 2024: $5.26BQ1 2025: $5.04BQ2 2025: $5.51BQ3 2025: $6.52BQ4 2025: $7.80BQ1 2026: $8.48BQ2 2026: $9.59B
Q1 2021Q2 2026
13F filings of Deerfield Management Company, L.P. (Series C) by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202682$9.59BNUVLBrookdale Sr Living IncRVMDvs. Q1 2026SEC
Q1 2026May 15, 202682$8.48BNUVLBrookdale Sr Living IncCOGTvs. Q4 2025SEC
Q4 2025Feb 17, 2026149$7.80BNUVLBrookdale Sr Living IncCOGTvs. Q3 2025SEC
Q3 2025Nov 14, 2025151$6.52BNUVLCNCMRUSvs. Q2 2025SEC
Q2 2025Aug 14, 2025124$5.51BNUVLOSCRVTRSvs. Q1 2025SEC
Q1 2025May 15, 2025122$5.04BNUVLVTRSIntegra Lifesciences Hldgs Cvs. Q4 2024SEC
Q4 2024Feb 14, 2025105$5.26BNUVLVTRSIntegra Lifesciences Hldgs Cvs. Q3 2024SEC
Q3 2024Nov 14, 2024443$6.69BNUVLVTRSCNCvs. Q2 2024SEC
Q2 2024Aug 14, 2024433$6.01BNUVLINSMED IncVTRSvs. Q1 2024SEC
Q1 2024May 15, 2024367$5.75BNUVLVTRSCNCvs. Q4 2023SEC
Q4 2023Feb 14, 2024222$5.42BNUVLGLAUKOS CorpVTRSvs. Q3 2023SEC
Q3 2023Nov 14, 202388$4.54BNUVLGLAUKOS CorpVTRSvs. Q2 2023SEC
Q2 2023Aug 14, 2023101$4.68BNUVLGLAUKOS CorpVTRSvs. Q1 2023SEC
Q1 2023May 15, 2023106$4.49BNUVLGLAUKOS CorpNBIXvs. Q4 2022SEC
Q4 2022Feb 14, 2023104$4.83BNUVLGLAUKOS CorpInvitae Corpvs. Q3 2022SEC
Q3 2022Nov 14, 2022129$5.01BNUVLGLAUKOS CorpAerie Pharmaceuticals Incvs. Q2 2022SEC
Q2 2022Aug 15, 2022126$4.75BGLAUKOS CorpNUVLVTRSvs. Q1 2022SEC
Q1 2022May 16, 2022121$4.47BGLAUKOS CorpNUVLVTRSvs. Q4 2021SEC
Q4 2021Feb 14, 2022125$4.75BNUVLVTRSAHCOvs. Q3 2021SEC
Q3 2021Nov 15, 2021132$5.11BNUVLVTRSInvitae Corpvs. Q2 2021SEC
Q2 2021Aug 16, 2021143$5.63BVTRSOMICInvitae Corpvs. Q1 2021SEC
Q1 2021May 17, 2021133$4.76BInvitae CorpVTRSNevro Corp–SEC

13D and 13G filings

Companies where Deerfield Management Company, L.P. (Series C) reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Deerfield Management Company, L.P. (Series C) does not currently report owning 5% or more of any company.

Latest filings

22 filings on file made by Deerfield Management Company, L.P. (Series C) or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Deerfield Management Company, L.P. (Series C)
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
HLSQTessera Defense & Homeland Security Inc.Jun 16, 20267:15 PM ETFlynn James Eand 5 others13D/A4.70%533.4K shares−3.39 ppfrom 8.09%Below 5%Jun 12, 2026SEC
HLSQTessera Defense & Homeland Security Inc.May 28, 20266:13 PM ETFlynn James Eand 5 others13D/A8.09%889.9K shares−1.90 ppfrom 9.99%May 26, 2026SEC
HLSQTessera Defense & Homeland Security Inc.Apr 15, 20265:37 PM ETFlynn James Eand 5 others13D/A9.99%989.1K shares0.00 ppfrom 9.99%Apr 15, 2026SEC
LRMRLarimar Therapeutics, Inc.Mar 2, 20267:46 PM ETFlynn James Eand 9 others13D/A34.41%35.7M shares−1.40 ppfrom 35.81%Feb 27, 2026SEC
HLSQTessera Defense & Homeland Security Inc.Feb 11, 20267:24 PM ETFlynn James Eand 5 others13D/A9.99%989.1K shares–Feb 9, 2026SEC
SPRYARS Pharmaceuticals, Inc.Aug 1, 20256:06 PM ETFlynn James Eand 5 others13D/A7.75%7.61M shares−1.04 ppfrom 8.79%Jul 30, 2025SEC
LRMRLarimar Therapeutics, Inc.Jul 31, 20256:26 PM ETFlynn James Eand 9 others13D/A35.81%30.7M shares–Jul 31, 2025SEC
SPRYARS Pharmaceuticals, Inc.Jul 22, 20257:38 PM ETFlynn James Eand 5 others13D/A8.79%8.63M shares−1.11 ppfrom 9.90%Jul 18, 2025SEC
SPRYARS Pharmaceuticals, Inc.Jul 2, 20258:24 AM ETFlynn James Eand 5 others13D/A9.90%9.72M shares−0.82 ppfrom 10.72%Jul 2, 2025SEC
SPRYARS Pharmaceuticals, Inc.Mar 24, 20257:57 PM ETFlynn James Eand 5 others13D/A10.72%10.5M shares–Mar 20, 2025SEC
HLSQTessera Defense & Homeland Security Inc.Mar 3, 20257:04 PM ETFlynn James Eand 5 others13D/A9.99%15.6M shares–Feb 27, 2025SEC
OMICSingular Genomics Systems, Inc.Feb 25, 20259:18 PM ETFlynn James Eand 3 others13D/A100.00%1.00K shares+93.38 ppfrom 6.62%Feb 21, 2025SEC
AFIBAcutus Medical, Inc.Jan 23, 20259:16 PM ETFlynn James Eand 5 others13D/A9.10%9.71M shares–Jan 21, 2025SEC
OMICSingular Genomics Systems, Inc.Dec 26, 20248:55 PM ETFlynn James Eand 3 others13D/A6.62%249.5K shares–Dec 22, 2024SEC
DALSDA32 Life Science Tech Acquisition Corp.Aug 1, 2023Deerfield Management Company, L.P. (Series C)13D/AOld format–––SEC
CMAXCareMax, Inc.Mar 13, 2023Deerfield Management Company, L.P. (Series C)13D/AOld format–––SEC
CMAXCareMax, Inc.Nov 7, 2022Deerfield Management Company, L.P. (Series C)13D/AOld format–––SEC
CMAXCareMax, Inc.Jun 2, 2022Deerfield Management Company, L.P. (Series C)13D/AOld format–––SEC
CMAXCareMax, Inc.Feb 15, 2022Deerfield Management Company, L.P. (Series C)13D/AOld format–––SEC
CMAXCareMax, Inc.Jan 28, 2022Deerfield Management Company, L.P. (Series C)13D/AOld format–––SEC